Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.32
-0.09 (-1.07%)
Nov 21, 2024, 10:54 AM EST - Market open
Amneal Pharmaceuticals Employees
Amneal Pharmaceuticals had 7,850 employees as of December 31, 2023. The number of employees increased by 250 or 3.29% compared to the previous year.
Employees
7,850
Change (1Y)
250
Growth (1Y)
3.29%
Revenue / Employee
$341,455
Profits / Employee
-$23,497
Market Cap
2.58B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
PACS Group | 32,433 |
Concentra Group Holdings Parent | 9,020 |
LivaNova | 2,900 |
Zai Lab | 2,175 |
ACADIA Pharmaceuticals | 598 |
TransMedics Group | 584 |
Scholar Rock Holding | 150 |
Apogee Therapeutics | 91 |
AMRX News
- 12 days ago - Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Amneal Reports Third Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Business Wire
- 6 weeks ago - Amneal to Report Third Quarter 2024 Results on November 8, 2024 - Business Wire
- 7 weeks ago - Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases - Business Wire
- 2 months ago - Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease - Business Wire
- 2 months ago - Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration - Business Wire
- 3 months ago - Melina Kennedy Joins the LDI, Ltd. Board of Managers - Business Wire